ENG
Endometriosis Market Industry Overview, Size, Share, Growth Trends, Research Insights and Forecast (2025–2032)
Endometriosis Market size was valued at USD 1.83 Bn in 2024 and the total Global Endometriosis Market revenue is expected to grow at a CAGR of 12.4% from 2025 to 2032, reaching nearly USD 4.66 Bn by 2032.
Format : PDF | Report ID : SMR_2702
Endometriosis Market Overview
Endometriosis is a chronic medical condition wherein tissue similar to the lining of the uterus (known as the endometrium) grows outside the uterus. This tissue discovered at the ovaries, fallopian tubes, outer floor of the uterus, and different pelvic organs. Like the uterine lining, this tissue thickens, breaks down, and bleeds with each menstrual cycle; however in contrast to everyday menstrual blood, the displaced tissue has no manner to exit the frame, leading to infection, ache, scar tissue, and adhesions.
One of the elements of the endometriosis market is the growing worldwide occurrence of the condition, particularly among women of reproductive age. With an anticipated 1 in 10 ladies affected worldwide, the developing reputation of endometriosis as a serious, persistent situation is fuelling call for powerful treatment options. As the affected person population keeps to grow, so does the urgency for innovative and accessible treatments, making disease occurrence a key motive force of endometriosis market expansion.
In 2024, a tremendous improvement within the endometriosis market is the combination of artificial intelligence (AI) into diagnostic and remedy making plans techniques. AI-driven gear is being utilized to examine massive datasets, along with scientific imaging, affected person histories, and symptom patterns, to aid in the early and accurate diagnosis of endometriosis.
To get more Insights: Request Free Sample Report
Endometriosis Market Dynamics
Rise in Infertility Linked to Endometriosis to Drive the Endometriosis Market
The developing incidence of infertility associated with endometriosis is an incredible driving agent of the endometriosis marketplace, as women are attempting to find early and effective interventions to maintain their reproductive fitness. Endometriosis purpose structural damage to reproductive organs and disrupt hormonal balance, appreciably reducing a women’s chances of conceiving. As infertility climb globally, and as attention of endometriosis as a contributing component grows, more patients are undergoing diagnostic opinions and pursuing fertility-preserving treatments.
Limited Awareness and Delayed Diagnosis to Restrain the Endometriosis Market
One tremendous restraint within the Endometriosis Market is the continual lack of expertise and delayed prognosis, which continues to limit timely treatment access. Despite growing advocacy, many women stay unaware of the condition or misinterpret its signs and symptoms as ordinary menstrual pain, often leading to years without right evaluation or remedy. Additionally, healthcare carriers also forget about or misdiagnose endometriosis because of its complicated and varied presentation. This diagnostic put off now not only worsens patient effects however also slows call for treatment solutions, making Endometriosis industry boom and delaying the adoption of latest treatment options.
Rising Demand for Personalized Medicine and Precision Treatment to Create Opportunities in the Endometriosis Market
The developing interest in personalized medication presents a giant possibility in the endometriosis market, as sufferers and clinicians are trying to find remedies tailored to individual organic profiles. Endometriosis varies substantially in severity, symptom presentation, and reaction to remedy, creating a one-size-fits-all technique much less powerful. Advances in genomics, biomarker identity, and patient-precise diagnostics are enabling extra focused and effective remedy techniques. Companies that invest in precision medicine offer more successful outcomes, reduce trial-and-error prescribing, and position themselves as leaders in a patient-centered market, capturing a loyal and growing customer base.
Endometriosis Market Segment Analysis
Based on Treatment, the endometriosis marketplace is segmented into hormone therapy, pain medication, surgical treatment, etc. The hormone remedy holds the first-rate percentage in the market endometriosis marketplace. This is usually due to its effectiveness in managing estrogen-powered growth of endometrial tissue, the underlying cause of the ailment.
Based on Drug Class, the endometriosis market is segmented into gonadotropin-releasing hormone agonist and antagonist, progestins, combined oral contraceptives, aromatase inhibitors, etc. Gonadotropin-releasing hormone (GNRH) dominates the endometriosis market due to their efficacy in decreasing estrogen, outdoor hormones for endometrial tissue growth.
Based on Route of administration, the endometriosis market is segmented into oral, injectables and topical. The oral segment holds the endometriosis industry, due to its comfort, affected female compliance and great availability. Oral medicinal capsules work without the clinic visits or expert administration, which is particularly attractive to patients managing a frequent situation.
Based on Distribution channel, the endometriosis market is segmented into retail pharmacies, hospital pharmacies, etc. The retail pharmacies segment is the major distribution channel in the marketplace, due to its access, consolation and adequate appearance. These pharmacies are more accessible to victims than health facilities-based shops, providing extended hours and accessible locations, which increase the adherence to endometriosis remedy.
Endometriosis Market Regional Analysis
North America Dominates the Endometriosis Market
North America holds the dominant position in the global endometriosis market, due to its superior healthcare infrastructure, high focus tiers, and sturdy presence of main pharmaceutical agencies. The region advantages from early diagnosis fees, substantial get entry to specialised gynaecological care, and sturdy reimbursement policies that assist the usage of each medical and surgical remedy options. Also, the U.S. is a hub for ongoing research and improvement, with common scientific trials and the rapid adoption of progressive cures, together with oral GnRH antagonists. Public awareness campaigns and sturdy advocacy for women’s health further make a contribution to a proactive technique towards managing endometriosis, making North America the most important and maximum advanced marketplace for endometriosis remedy.
Endometriosis Market Competitive Landscape
In January 2024, Pfizer and Sumitomo Pharma initiated the launch of MYFEMBREE (a mixture of relugolix, estradiol, and norethisterone acetate), increasing treatment options for endometriosis. This new oral remedy presents an opportunity to conventional injectables and hormonal remedies, providing powerful symptom remedy with the ease of daily tablet. Its entry into the market underscores persevered investment in greater centered and patient-friendly treatments for endometriosis and represents a strategic growth through Pfizer into the reproductive fitness space.
Endometriosis Market Scope Table
|
|
Endometriosis Market Scope |
|||
|
|
Market Size in 2024 |
1.83 Bn. |
||
|
|
Market Size in 2032 |
4.66 Bn. |
||
|
|
CAGR (2025-2032) |
12.4% |
||
|
|
Historic Data |
2019-2024 |
||
|
|
Base Year |
2024 |
||
|
|
Forecast Period |
2025-2032 |
||
|
|
Segments Analysis |
By Treatment Hormone therapy Pain medication Surgical treatment Others |
||
|
|
By Drug Class Progestins Combined Oral Contraceptives Aromatase Inhibitors Others |
|||
|
|
By Route of Administration Oral Injectables Topical |
|||
|
|
By Distribution Channel Retail Pharmacies Hospital Pharmacies Others |
|||
|
Regional Scope |
North America: United States, Canada, Mexico Europe: United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe Asia Pacific (APAC): China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC Middle East & Africa (MEA): South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America |
|
||
Endometriosis Market Key Players include:
North America
- Pfizer Inc. (US)
- AbbVie Inc. (US)
- Neurocrine Biosciences (US)
- Meditrina Pharmaceuticals (US)
- Cellmatix Therapeutics (US)
- Bausch Health Companies Inc. (Canada)
Europe
- Theramex (UK)
- Ananda Pharma (UK)
- Bayer AG (Germany)
- NETRIS Pharma (France)
- Insud Pharma (Spain)
Asia Pacific
- Kissei Pharmaceutical (Japan)
- Kokilaben Dhirubhai Ambani Hospital (India)
- Bio Genuine (China)
- Hera Biotech (China)
Middle East and Africa
- Endometriosis Institute (South Africa)
- Medfem Fertility Clinic (South Africa)
- GYNESCOPE (Nigeria)
- Dr. Ilker Kahramano?lu Clinic (Turkey)
South America
- Besins Healthcare (Brazil)
- Ipsen Pharma (Brazil)
- Teva Pharmaceutical Industries (Peru)
Frequently Asked Questions
North America is the leading region in Endometriosis Market in 2024.
Primary Treatment for the Endometriosis Market includes hormone therapy, pain medication, surgical treatment, etc.
A significant challenge in the Endometriosis Market is limited awareness and delay diagnosis of the endometriosis.
Pfizer Inc. (United States), AbbVie Inc., Neurocrine Biosciences, Meditrina Pharmaceuticals, Cellmatix Therapeutics, etc are the leading companies in the Endometriosis Treatment Industry.
1. Endometriosis Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Endometriosis Market: Competitive Landscape
2.1. SMR Competition Matrix
2.2. Key Players Benchmarking
2.2.1. Company Name
2.2.2. Service Segment
2.2.3. Distribution Channel Segment
2.2.4. Revenue (2024)
2.2.5. Geographical Presence
2.3. Market Structure
2.3.1. Market Leaders
2.3.2. Market Followers
2.3.3. Emerging Players
2.4. Mergers and Acquisitions Details
3. Endometriosis Market: Dynamics
3.1. Endometriosis Market Trends
3.2. Endometriosis Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
3.5. Regulatory Landscape by Region
3.6. Key Opinion Leader Analysis for the Global Industry
3.7. Analysis of Government Schemes and Initiatives for Industry
4. Endometriosis Market: Global Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032)
4.1. Endometriosis Market Size and Forecast, By Treatment (2024-2032)
4.1.1. Hormone therapy
4.1.2. Pain medication
4.1.3. Surgical treatment
4.1.4. Others
4.2. Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
4.2.1. Progestins
4.2.2. Combined Oral Contraceptives
4.2.3. Aromatase Inhibitors
4.2.4. Others
4.3. Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
4.3.1. Oral
4.3.2. Injectables
4.3.3. Topical
4.4. Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
4.4.1. Retail Pharmacies
4.4.2. Hospital Pharmacies
4.4.3. Others
4.5. Endometriosis Market Size and Forecast, By Region (2024-2032)
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Middle East and Africa
4.5.5. South America
5. North America Endometriosis Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032)
5.1. North America Endometriosis Market Size and Forecast, By Treatment (2024-2032)
5.1.1. Hormone therapy
5.1.2. Pain medication
5.1.3. Surgical treatment
5.1.4. Others
5.2. North America Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
5.2.1. Progestins
5.2.2. Combined Oral Contraceptives
5.2.3. Aromatase Inhibitors
5.2.4. Others
5.3. North America Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
5.3.1. Oral
5.3.2. Injectables
5.3.3. Topical
5.4. North America Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
5.4.1. Retail Pharmacies
5.4.2. Hospital Pharmacies
5.4.3. Others
5.5. North America Endometriosis Market Size and Forecast, by Country (2024-2032)
5.5.1. United States
5.5.1.1. United States Endometriosis Market Size and Forecast, By Treatment (2024-2032)
5.5.1.1.1. Hormone therapy
5.5.1.1.2. Pain medication
5.5.1.1.3. Surgical treatment
5.5.1.1.4. Others
5.5.1.2. United States Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
5.5.1.2.1. Progestins
5.5.1.2.2. Combined Oral Contraceptives
5.5.1.2.3. Aromatase Inhibitors
5.5.1.2.4. Others
5.5.1.3. United States Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
5.5.1.3.1. Oral
5.5.1.3.2. Injectables
5.5.1.3.3. Topical
5.5.1.4. United States Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
5.5.1.4.1. Retail Pharmacies
5.5.1.4.2. Hospital Pharmacies
5.5.1.4.3. Others
5.5.2. Canada
5.5.2.1. Canada Endometriosis Market Size and Forecast, By Treatment (2024-2032)
5.5.2.1.1. Hormone therapy
5.5.2.1.2. Pain medication
5.5.2.1.3. Surgical treatment
5.5.2.1.4. Others
5.5.2.2. Canada Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
5.5.2.2.1. Progestins
5.5.2.2.2. Combined Oral Contraceptives
5.5.2.2.3. Aromatase Inhibitors
5.5.2.2.4. Others
5.5.2.3. Canada Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
5.5.2.3.1. Oral
5.5.2.3.2. Injectables
5.5.2.3.3. Topical
5.5.2.4. Canada Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
5.5.2.4.1. Retail Pharmacies
5.5.2.4.2. Hospital Pharmacies
5.5.2.4.3. Others
5.5.3. Mexico
5.5.3.1. Mexico Endometriosis Market Size and Forecast, By Treatment (2024-2032)
5.5.3.1.1. Hormone therapy
5.5.3.1.2. Pain medication
5.5.3.1.3. Surgical treatment
5.5.3.1.4. Others
5.5.3.2. Mexico Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
5.5.3.2.1. Progestins
5.5.3.2.2. Combined Oral Contraceptives
5.5.3.2.3. Aromatase Inhibitors
5.5.3.2.4. Others
5.5.3.3. Mexico Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
5.5.3.3.1. Oral
5.5.3.3.2. Injectables
5.5.3.3.3. Topical
5.5.3.4. Mexico Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
5.5.3.4.1. Retail Pharmacies
5.5.3.4.2. Hospital Pharmacies
5.5.3.4.3. Others
6. Europe Endometriosis Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032)
6.1. Europe Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.2. Europe Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.3. Europe Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.4. Europe Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5. Europe Endometriosis Market Size and Forecast, by Country (2024-2032)
6.5.1. United Kingdom
6.5.1.1. United Kingdom Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.1.2. United Kingdom Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.1.3. United Kingdom Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.1.4. United Kingdom Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.2. France
6.5.2.1. France Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.2.2. France Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.2.3. France Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.2.4. France Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.3. Germany
6.5.3.1. Germany Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.3.2. Germany Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.3.3. Germany Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.3.4. Germany Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.4. Italy
6.5.4.1. Italy Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.4.2. Italy Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.4.3. Italy Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.4.4. Italy Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.5. Spain
6.5.5.1. Spain Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.5.2. Spain Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.5.3. Spain Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.5.4. Spain Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.6. Sweden
6.5.6.1. Sweden Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.6.2. Sweden Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.6.3. Sweden Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.6.4. Sweden Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.7. Russia
6.5.7.1. Russia Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.7.2. Russia Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.7.3. Russia Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.7.4. Russia Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
6.5.8. Rest of Europe
6.5.8.1. Rest of Europe Endometriosis Market Size and Forecast, By Treatment (2024-2032)
6.5.8.2. Rest of Europe Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
6.5.8.3. Rest of Europe Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
6.5.8.4. Rest of Europe Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7. Asia Pacific Endometriosis Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032)
7.1. Asia Pacific Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.2. Asia Pacific Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.3. Asia Pacific Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.4. Asia Pacific Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5. Asia Pacific Endometriosis Market Size and Forecast, by Country (2024-2032)
7.5.1. China
7.5.1.1. China Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.1.2. China Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.1.3. China Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.1.4. China Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.2. S Korea
7.5.2.1. S Korea Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.2.2. S Korea Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.2.3. S Korea Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.2.4. S Korea Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.3. Japan
7.5.3.1. Japan Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.3.2. Japan Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.3.3. Japan Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.3.4. Japan Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.4. India
7.5.4.1. India Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.4.2. India Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.4.3. India Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.4.4. India Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.5. Australia
7.5.5.1. Australia Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.5.2. Australia Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.5.3. Australia Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.5.4. Australia Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.6. Indonesia
7.5.6.1. Indonesia Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.6.2. Indonesia Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.6.3. Indonesia Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.6.4. Indonesia Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.7. Malaysia
7.5.7.1. Malaysia Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.7.2. Malaysia Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.7.3. Malaysia Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.7.4. Malaysia Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.8. Philippines
7.5.8.1. Philippines Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.8.2. Philippines Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.8.3. Philippines Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.8.4. Philippines Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.9. Thailand
7.5.9.1. Thailand Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.9.2. Thailand Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.9.3. Thailand Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.9.4. Thailand Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.10. Vietnam
7.5.10.1. Vietnam Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.10.2. Vietnam Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.10.3. Vietnam Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.10.4. Vietnam Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
7.5.11. Rest of Asia Pacific
7.5.11.1. Rest of Asia Pacific Endometriosis Market Size and Forecast, By Treatment (2024-2032)
7.5.11.2. Rest of Asia Pacific Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
7.5.11.3. Rest of Asia Pacific Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
7.5.11.4. Rest of Asia Pacific Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8. Middle East and Africa Endometriosis Market Size and Forecast (by Value in USD Bn) (2024-2032)
8.1. Middle East and Africa Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.2. Middle East and Africa Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.3. Middle East and Africa Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.4. Middle East and Africa Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8.5. Middle East and Africa Endometriosis Market Size and Forecast, by Country (2024-2032)
8.5.1. South Africa
8.5.1.1. South Africa Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.5.1.2. South Africa Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.5.1.3. South Africa Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.5.1.4. South Africa Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8.5.2. GCC
8.5.2.1. GCC Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.5.2.2. GCC Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.5.2.3. GCC Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.5.2.4. GCC Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8.5.3. Egypt
8.5.3.1. Egypt Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.5.3.2. Egypt Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.5.3.3. Egypt Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.5.3.4. Egypt Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8.5.4. Nigeria
8.5.4.1. Nigeria Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.5.4.2. Nigeria Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.5.4.3. Nigeria Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.5.4.4. Nigeria Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
8.5.5. Rest of ME&A
8.5.5.1. Rest of ME&A Endometriosis Market Size and Forecast, By Treatment (2024-2032)
8.5.5.2. Rest of ME&A Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
8.5.5.3. Rest of ME&A Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
8.5.5.4. Rest of ME&A Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9. South America Endometriosis Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032)
9.1. South America Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.2. South America Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.3. South America Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.4. South America Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9.5. South America Endometriosis Market Size and Forecast, by Country (2024-2032)
9.5.1. Brazil
9.5.1.1. Brazil Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.5.1.2. Brazil Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.5.1.3. Brazil Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.5.1.4. Brazil Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9.5.2. Argentina
9.5.2.1. Argentina Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.5.2.2. Argentina Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.5.2.3. Argentina Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.5.2.4. Argentina Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9.5.3. Colombia
9.5.3.1. Colombia Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.5.3.2. Colombia Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.5.3.3. Colombia Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.5.3.4. Colombia Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9.5.4. Chile
9.5.4.1. Chile Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.5.4.2. Chile Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.5.4.3. Chile Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.5.4.4. Chile Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
9.5.5. Rest Of South America
9.5.5.1. Rest Of South America Endometriosis Market Size and Forecast, By Treatment (2024-2032)
9.5.5.2. Rest Of South America Endometriosis Market Size and Forecast, By Drug Class (2024-2032)
9.5.5.3. Rest Of South America Endometriosis Market Size and Forecast, By Route of Administration (2024-2032)
9.5.5.4. Rest Of South America Endometriosis Market Size and Forecast, By Distribution Channel (2024-2032)
10. Company Profile: Key Players
10.1. Pfizer Inc
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Recent Developments
10.2. AbbVie Inc.
10.3. Neurocrine Biosciences
10.4. Meditrina Pharmaceuticals
10.5. Cellmatix Therapeutics
10.6. Bausch Health Companies Inc.
10.7. Theramex
10.8. Ananda Pharma
10.9. Bayer AG
10.10. NETRIS Pharma
10.11. Insud Pharma
10.12. Kissei Pharmaceutical
10.13. Kokilaben Dhirubhai Ambani Hospital
10.14. Bio Genuine
10.15. Hera Biotech
10.16. Endometriosis Institute
10.17. Medfem Fertility Clinic
10.18. GYNESCOPE
10.19. Dr. Ilker Kahramano?lu Clinic
10.20. Besins Healthcare
10.21. Ipsen Pharma
10.22. Teva Pharmaceutical Industries
11. Key Findings
12. Industry Recommendations
13. Endometriosis Market: Research Methodology
